Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era
Author:
Affiliation:
1. Deparment of Medicine; Memorial Sloan Kettering Cancer Center; New York NY USA
2. Department of Epidemiology and Biostatistics; Sloan Kettering Cancer Center; New York NY USA
Funder
NIH Training
NIH Core
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14453/fullpdf
Reference40 articles.
1. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens;Ardeshna;British Journal of Haematology,2005
2. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999
3. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007
4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;New England Journal of Medicine,2002
5. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation;Costa;British Journal of Haematology,2008
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era;BMC Cancer;2024-01-13
2. CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma;Cureus;2023-09-01
3. Hypofractionated Radiotherapy for Refractory or Relapsed Aggressive B-cell Lymphoma in the Rituximab Era;2023-08-30
4. Diffuse large B‑cell lymphoma and monoclonal gammopathy secondary to immune thrombocytopenic purpura: A case report;Oncology Letters;2023-04-19
5. Indications for Autologous Stem Cell Transplant;Basics of Hematopoietic Stem Cell Transplant;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3